Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC008 (ulviprubart) in inclusion body myositis
2022-501925-19-00Phase 3Completed
- Sponsor
- Abcuro
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in inclusion body myositis (IBM) comparing ulviprubart with placebo (2 arms). Primary endpoints: Change from baseline in IBMFRS at Week 76 and Pharmacodynamic recovery of KLRG1+ cells. Started Jan 2024; status: completed.
02
Drugs
ulviprubart
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2022-501925-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501925-19-00.